Have you evaluated the performance of The Beauty Health Company's (SKIN) international operations for the quarter ending December 2025? Given the extensive global presence of this company, analyzing the patterns in international revenues is crucial for understanding its financial strength and potential for growth.In today's increasingly interconnected global economy, a company's ability to tap into international markets can be a pivotal factor in shaping its overall financial health and growth trajectory. ...

Core Insights - The Beauty Health Company (SKIN) has set a revenue target of $285 million to $305 million for 2026, focusing on increasing utilization of its installed base and driving innovation [2] Management Perspective - CEO Pedro Malha emphasized his confidence in the long-term potential of Beauty Health, highlighting the company's globally recognized brand, substantial installed base of systems, and a consumables model that supports growth [2]

Core Insights - The Beauty Health Company (SKIN) reported a revenue of $82.4 million for Q4 2025, reflecting a year-over-year decline of 1.3% and an EPS of -$0.06, an improvement from -$0.08 a year ago [1] - The revenue exceeded the Zacks Consensus Estimate of $78.17 million by 5.42%, and the EPS also surpassed the consensus estimate of -$0.07 by 7.69% [1] Revenue Breakdown - Geographic Revenue in the Americas was $57.4 million, surpassing the average estimate of $53.65 million, with a year-over-year change of +0.5% [4] - Geographic Revenue in EMEA reached $18.8 million, exceeding the estimated $17.2 million, representing a +9.3% change year-over-year [4] - Geographic Revenue in Asia Pacific (APAC) was $6.1 million, below the average estimate of $7.49 million, showing a significant year-over-year decline of -33.7% [4] Sales Performance - Delivery Systems Net Sales amounted to $24.7 million, exceeding the estimated $20.85 million, but reflecting a year-over-year decline of -7.8% [4] - Consumables Net Sales were reported at $57.7 million, slightly above the average estimate of $57.34 million, indicating a year-over-year increase of +1.8% [4] Stock Performance - Shares of Beauty Health have returned +6.1% over the past month, contrasting with the Zacks S&P 500 composite's -2.3% change [3] - The stock currently holds a Zacks Rank 4 (Sell), suggesting potential underperformance relative to the broader market in the near term [3]

分组1 - The Beauty Health Company (SKIN) reported a quarterly loss of $0.06 per share, better than the Zacks Consensus Estimate of a loss of $0.07, and improved from a loss of $0.08 per share a year ago, resulting in an earnings surprise of +7.69% [1] - The company posted revenues of $82.4 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 5.42%, although this represents a decline from year-ago revenues of $83.5 million [2] - Beauty Health has surpassed consensus EPS estimates three times over the last four quarters and has topped consensus revenue estimates four times during the same period [2] 分组2 - The stock has underperformed, losing about 19.1% since the beginning of the year, compared to a 1% decline in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.04 on revenues of $69.33 million, and for the current fiscal year, it is -$0.18 on revenues of $302.8 million [7] - The Zacks Industry Rank indicates that the Medical Services sector is in the bottom 43% of over 250 Zacks industries, suggesting potential underperformance compared to higher-ranked industries [8]

Core Insights - The Beauty Health Company is positioned for long-term growth in the professional skin health market, leveraging its established brand and technology to enhance commercial execution and operational discipline [1][5][24]. Financial Performance - In Q4 2025, total revenue was $82.4 million, a decrease of 1.3% year-over-year, with consumables revenue increasing to $57.7 million, up 1.7% from the previous year [11][29]. - Device revenue was $24.7 million, down 7.9% year-over-year, but showed improvement compared to Q3 [11]. - Adjusted gross margin expanded to 67.4%, while GAAP gross margin increased to 64.4%, driven by a favorable shift towards consumables revenue [12][30]. - Adjusted EBITDA for Q4 was $15 million, up from $9 million in the prior year, indicating a margin expansion of approximately 700 basis points [12][31]. - For the full year 2025, net sales totaled $300.8 million, down from $334.3 million in 2024, with adjusted EBITDA increasing to $45.1 million from $12.3 million [27]. Market Trends - The U.S. medspa market has expanded significantly, growing from approximately 1,600 locations in 2010 to over 13,000 today, indicating strong consumer interest in skin health [6]. - Consumers are increasingly investing in skin health as a lifestyle choice, seeking clinically proven outcomes and natural results [6][9]. - The market is shifting towards combination therapies and clinically validated results, favoring companies with strong provider education and recurring revenue models [15][16]. Strategic Initiatives - The company aims to enhance its commercial model by focusing on device utilization rather than just placement, which is expected to drive long-term growth [10][14]. - Key priorities include improving salesforce excellence, marketing discipline, and focused innovation to strengthen the installed base and expand the role of HydraFacial in provider practices [17][20][22]. - The company plans to launch a next-generation HydraFacial system by 2028, aimed at enhancing the value proposition for providers [57]. Guidance and Outlook - For 2026, the company expects revenue to be in the range of $285 million to $305 million, with positive adjusted EBITDA of $35 million to $45 million, reflecting a focus on execution and stabilization [32][33]. - The first quarter of 2026 is projected to have revenue of $63 million to $68 million, typically the lowest revenue quarter due to seasonal dynamics [35]. - The company anticipates returning to growth in 2027 as operational changes take effect and innovation scales [34][37].

Financial Data and Key Metrics Changes - For Q4 2025, total revenue was $82.4 million, a decrease of 1.3% year-over-year, but an improvement from the double-digit decline in Q3 [10] - Consumables revenue increased to $57.7 million from $56.7 million, representing a growth of 1.7% year-over-year [10] - Device revenue was $24.7 million, down 7.9% year-over-year, but showed improvement compared to Q3 [10] - Adjusted gross margin expanded to 67.4%, while GAAP gross margin increased to 64.4% [11] - Adjusted EBITDA for Q4 was $15 million, up from $9 million in the prior year, marking a significant margin expansion [11] - For the full year, net sales were $300.8 million, down from $334.3 million in 2024, with adjusted EBITDA increasing to $45.1 million from $12.3 million [21][22] Business Line Data and Key Metrics Changes - The company placed over 1,000 devices in Q4, ending the year with over 36,000 systems in the global install base [12] - The installed base is viewed as underutilized, with potential for significant consumables revenue growth through improved utilization [12] Market Data and Key Metrics Changes - The U.S. med spa market has grown from approximately 1,600 locations in 2010 to over 13,000 today, indicating a significant market expansion [7] - Consumer demographics are evolving, with increased engagement from men, Gen Z, and younger consumers seeking skin health treatments [7][8] Company Strategy and Development Direction - The company aims to shift from a device placement model to a device utilization model to drive long-term growth [9] - Key strategic priorities include salesforce excellence, marketing discipline, and focused innovation [14] - The company plans to enhance its commercial model by improving provider education and marketing strategies [16][18] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about the demand for non-invasive treatments, despite macroeconomic pressures affecting capital equipment sales [12][39] - The first half of 2026 is expected to be modestly below the prior year, with a stronger trajectory anticipated in the second half [25][28] - The company expects to return to growth in 2027 as operational changes take effect [19][28] Other Important Information - The company has strengthened its balance sheet and improved its cost structure, exiting 2025 in a stronger position than the previous year [20] - The average spend per treatment in the U.S. for consumables is up 10% year-over-year, driven by premium boosters [62] Q&A Session Summary Question: Guidance for 2026 and sales organization overhaul - Management expects revenue to be flat year-on-year, with Adjusted EBITDA slightly below 2025 due to reinvestment in R&D [32][33] Question: Underlying market environment assumptions - Consumer spending remains selective, with a focus on clinically proven results; the aesthetics category has faced pressure due to credit tightness [38][39] Question: Churn trends and marketing to new demographics - Churn improved in Q4 to about 1.1%, with expectations to hold flat year-over-year; marketing strategies are being adjusted to target new demographics [46][49] Question: New system launch timeline and features - The next-generation HydraFacial is planned for launch in 2028, aimed at providing compelling reasons for upgrades [55] Question: Consumables performance and pricing strategy - A 5% price increase on consumables was well-received, and the company is evaluating overall pricing strategy moving forward [76]

Financial Data and Key Metrics Changes - For Q4 2025, total revenue was $82.4 million, a decrease of 1.3% year-over-year, but an improvement from the double-digit decline in Q3 [10] - Consumables revenue increased to $57.7 million from $56.7 million, representing a growth of 1.7% year-over-year [10] - Device revenue was $24.7 million, down 7.9% year-over-year, but showed improvement compared to Q3 [10] - Adjusted gross margin expanded to 67.4%, while GAAP gross margin increased to 64.4% [11] - Adjusted EBITDA for Q4 was $15 million, up from $9 million in the prior year, indicating a margin expansion of approximately 700 basis points [11] - For the full year, net sales were $300.8 million, down from $334.3 million in 2024, with consumables revenue totaling $212.7 million and device revenue at $88.1 million [21] Business Line Data and Key Metrics Changes - The installed base of systems reached over 36,000 globally, with more than 1,000 devices placed in Q4 [12] - The capital equipment segment continues to face pressure, consistent with broader macroeconomic conditions [10] Market Data and Key Metrics Changes - The U.S. med spa market has grown from approximately 1,600 locations in 2010 to over 13,000 today, indicating significant market expansion [7] - Consumer demographics are evolving, with increased engagement from men, Gen Z, and younger consumers [7] Company Strategy and Development Direction - The company aims to shift from a device placement model to a device utilization model to drive long-term growth [9] - Key strategic priorities include salesforce excellence, marketing discipline, and focused innovation [14] - The company plans to enhance its commercial model by improving provider education and marketing strategies [16][17] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about the aesthetic category, noting that demand for non-invasive treatments continues to grow globally [12] - The first half of 2026 is expected to be modestly below the prior year, with a stronger trajectory anticipated in the second half [19][25] - The company expects to return to growth in 2027 as operational changes take effect [28] Other Important Information - The company has strengthened its balance sheet and improved its cost structure, exiting 2025 as a stronger entity [20] - Adjusted EBITDA for the full year increased significantly to $45.1 million from $12.3 million in the prior year [21] Q&A Session Summary Question: Guidance for 2026 and sales organization overhaul - Management expects revenue to be flat year-on-year, with adjusted EBITDA slightly below 2025 due to reinvestment in R&D [32][33] Question: Underlying market environment assumptions - Consumer spending remains selective, with a focus on clinically proven results at accessible price points [37] - The medical segment continues to grow, driven by med spas using HydraFacial to attract patients [39] Question: Churn trends and marketing to new demographics - Churn improved in Q4 to about 1.1%, with expectations to hold flat year-over-year [44] - The company is addressing the needs of new demographics entering the category, focusing on outcome-driven protocols [47] Question: New system launch timeline and features - The next-generation HydraFacial is planned for launch in 2028, aimed at providing compelling reasons for upgrades [53] Question: Pricing strategy and consumable utilization - A 5% price increase on consumables was well-received, with no significant complaints [73] - Providers who understand how to prescribe boosters use them three times more than those who do not [74]

Financial Data and Key Metrics Changes - For Q4 2025, total revenue was $82.4 million, a decrease of 1.3% year-over-year, but an improvement from the double-digit decline in Q3 [9][21] - Consumables revenue increased to $57.7 million from $56.7 million, representing a growth of 1.7% year-over-year [9] - Device revenue was $24.7 million, down 7.9% year-over-year, but showed improvement compared to Q3 [9] - Adjusted gross margin expanded to 67.4%, while GAAP gross margin increased to 64.4% [10][22] - Adjusted EBITDA for Q4 was $15 million, up from $9 million in the prior year, indicating a margin expansion of approximately 700 basis points [10][23] - For the full year, net sales were $300.8 million, down from $334.3 million in 2024, with consumables revenue totaling $212.7 million and device revenue at $88.1 million [20] Business Line Data and Key Metrics Changes - The company placed over 1,000 devices in Q4, ending the year with over 36,000 systems in its global install base [11] - The installed base is viewed as underutilized, with potential for significant consumables revenue growth through improved utilization [11] Market Data and Key Metrics Changes - The U.S. med spa market has grown from approximately 1,600 locations in 2010 to over 13,000 today, indicating a significant market expansion [6] - Consumer demographics are evolving, with increased engagement from men, Gen Z, and younger consumers seeking skin health treatments [6][7] Company Strategy and Development Direction - The company aims to shift its model from device placement to device utilization, focusing on unlocking the economic potential of its installed base [8] - Key strategic priorities include salesforce excellence, marketing discipline, and focused innovation [12][14] - The company plans to enhance its product ecosystem and strengthen its market position through disciplined innovation and targeted marketing efforts [15][16] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about the aesthetic category, noting that demand for non-invasive treatments continues to grow globally [11] - The first half of 2026 is expected to be modestly below the prior year, with a stronger trajectory anticipated in the second half as execution initiatives take hold [17][24] - The company expects to return to growth in 2027, driven by operational changes and innovation [17][26] Other Important Information - The company ended 2025 with approximately $232.7 million in cash equivalents, a decrease from $370.1 million in 2024, primarily due to debt restructuring [21] - The company is focusing on improving its balance sheet and financial discipline, which has contributed to its stabilization [10][18] Q&A Session Summary Question: Guidance for 2026 and sales organization overhaul - Management expects revenue to be flat year-on-year, with Adjusted EBITDA slightly below 2025 due to reinvestment in R&D for future innovation [30][31] Question: Underlying market environment assumptions - Consumer spending remains selective, with a focus on clinically proven results at accessible price points, impacting procedure volume and device placements [36][37] Question: Churn trends and marketing to new demographics - Churn improved in Q4 to about 1.1%, with a focus on restructuring sales and customer service teams to better support smaller accounts [41][43] - The company is addressing the needs of new demographics, including men and Gen Z, by positioning HydraFacial as a lifestyle routine [45][46] Question: New system launch timeline and additional services - The next-generation HydraFacial is in early development, with a planned launch in 2028, aimed at providing compelling reasons for upgrades [51][52] Question: Consumables performance and pricing strategy - The company successfully implemented a 5% price increase on consumables without significant pushback, and is evaluating overall pricing strategy moving forward [74]

Financial Performance - Net sales for the year ended December 31, 2025, decreased by $33.5 million, or 10.0%, compared to 2024, with Delivery Systems net sales down by $37.3 million, or 29.8%[488] - Consumables net sales increased by $3.8 million, or 1.8%, primarily due to increased placements of Delivery Systems and price increases, despite the transition to a distributor partner in China[489] - The company reported a net loss of $9.5 million, or 3.2% of net sales, compared to a net loss of $29.1 million, or 8.7% in 2024[486] Cost and Expenses - Cost of sales decreased by $47.6 million, or 31.3%, leading to a gross profit increase of $14.1 million, or 7.7%, and a gross margin improvement to 65.3% from 54.5%[490] - Selling and marketing expenses decreased by $24.7 million, or 20.9%, as a percentage of net sales fell to 31.1% from 35.4%[491] - Research and development expenses decreased by $0.7 million, or 10.6%, remaining at 1.9% of net sales[492] - Total operating expenses were $217.2 million, or 72.2% of net sales, compared to $250.1 million, or 74.8% in 2024[487] - General and administrative expenses decreased by $7.5 million, or 6.0%, to $117.9 million in 2025 from $125.5 million in 2024, primarily due to lower personnel-related expenses[493] Interest and Financing - Interest expense increased to $19.3 million, or 6.4% of net sales, from $10.4 million, or 3.1% in 2024[487] - Interest expense increased by $8.9 million, or 85.6%, to $19.3 million in 2025 compared to $10.4 million in 2024, mainly due to interest and amortization of debt issuance costs related to the 2028 Notes[494] - Interest income decreased by $7.7 million, or 46.2%, to $(9.0) million in 2025 from $(16.6) million in 2024, primarily due to lower average invested balances[495] Cash Flow and Liquidity - The company had cash, cash equivalents, and restricted cash of $232.7 million as of December 31, 2025, down from $370.1 million at the beginning of the year[498] - Net cash provided by operating activities was $37.5 million in 2025, compared to $16.1 million in 2024, reflecting improved operational efficiency[516] - Net cash provided by operating activities for the year ended December 31, 2025 was $37.5 million, up from $16.1 million in 2024, primarily due to changes in working capital and non-cash adjustments[517] - Net cash used for investing activities decreased to $5.2 million in 2025 from $6.8 million in 2024, attributed to lower capital expenditures[518] - Net cash used for financing activities increased to $174.9 million in 2025 from $158.3 million in 2024, mainly related to the exchange and repurchases of the Company's 2026 Notes[519] Market and Economic Conditions - The company transitioned sales in the China market to a distributor partner, discontinuing direct sales to customers in that region[475] - The company remains vigilant regarding economic and geopolitical conditions that may impact future performance and is implementing risk mitigation strategies[471] - The Company continues to face macroeconomic challenges that could adversely impact revenues and earnings going forward[511] - Inflation has adversely affected the Company's liquidity and overall cost structure, with expectations of continued cost increases if inflation persists[541] Foreign Currency and Interest Rate Risks - An adverse 10% foreign currency exchange rate change would have resulted in an adverse effect on income before income taxes of approximately $4 million and $6 million for the years ended December 31, 2025 and 2024, respectively[538] - A hypothetical 100 basis points increase in interest rates would have resulted in an increase in the fair market value of the investment portfolio by approximately $1 million and $3 million as of December 31, 2025 and 2024, respectively[536] - The Company has not engaged in the hedging of foreign currency transactions to date, although it may consider doing so in the future[539] Inventory and Revenue Recognition - The Company recognized revenue of approximately $17 million for the year ended December 31, 2023 from the estimated fair value of refurbished Delivery Systems, with no trade-in revenue recognized for 2025 and 2024[521] - The Company experienced approximately $7 million of inventory charges related to the write-down of trade-in Delivery Systems to its net realizable value during the year ended December 31, 2024[522] - Total contractual obligations as of December 31, 2025, amounted to $471.6 million, with $124.5 million due within one year[514] - The Company does not rely on projected income to support the realization of deferred tax assets due to cumulative pre-tax losses as of December 31, 2025[531]

Q4 & Full Year 2025 Financial Results March 12, 2026 Disclaimer This Presentation contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may relate to, but are not limited to, expectations of future operating results or financial performance of The Beauty Health Company (the "Company"), capital expenditures, the introduction of new products, market strategy a ...